Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.

Condition:   Metastatic Castration-resistent Prostate Cancer Interventions:   Drug: Docetaxel;   Drug: Abiraterone Acetate or Enzalutamide Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials